Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

The present invention relates to antimicrobial peptides derived from Romo1 protein, and provides various peptides having the amino acid sequence of the α-helix 2 region of the Romo1 protein and an antibacterial composition containing each of the peptides, as a result of confirming that the peptides have antibacterial activity against gram-positive, gram-negative and multidrug-resistant bacteria. The Romo1-derived peptides and variants thereof have better bactericidal capability against various types of bacteria and multidrug-resistant bacteria than existing antibiotics and antibiotic peptides, and have antibacterial activity against various bacteria in blood vessels, and are novel antibiotics that may be provided as substances for the prevention or treatment of a wide range of bacterial infectious diseases. A composition containing the antimicrobial peptide of the present invention is suitable for various applications, including drugs, quasi-drugs, food and feed additives, pesticides and cosmetic additives, to prevent or treat infectious diseases.

Compositions and methods are provided for producing crystalline forms of organic acids or salts or lactones thereof from an aqueous solution. More specifically, methods are provided for producing a crystalline form of a salt of mevalonic acid (also referred to as X-MVA) from an aqueous solution, comprising subjecting the aqueous solution comprising said X-MVA to a purification step to produce a purified solution and crystallizing said X-MVA from said purified solution by water solvent crystallization. Methods are also provided for producing mevalonolactone from an aqueous solution comprising X-MVA, comprising subjecting the aqueous solution comprising said X-MVA to cation exchange thereby converting said aqueous solution comprising X-MVA to an aqueous solution comprising mevalonolactone (MVL). Methods are also provided for producing mevalonolactone monohydrate crystals.

Compositions for promoting intestinal health are disclosed and described. In one example, the composition can include a combination of cyanidins and delphinidins, in an amount sufficient to treat intestinal hyperpermeability. In a further example, the composition can further comprise a prebiotic blend and fructooligosaccharides. Further presented herein, is a method of treating a condition or disorder related to gastrointestinal health in a subject. In one example, the method can include maximizing tight junction integrity in epithelial cells of gastrointestinal tract of the subject.

A solid dosage form comprises an inner core containing a cycloserine compound and an outer layer attached to the inner core. The dosage form can be enteric tablet or transdermal patch, suitable for treating a neuropsychiatric disorder or tuberculosis.

The present invention relates to a use of agar-derived oligosaccharides for inhibiting the growth of Staphylococcus. More specifically, the present invention provides, as a material for medicine, food, cosmetics and the like, a use of agar-derived agarooligosaccharides, agarobiose or AHG, which have an effect of inhibiting the growth of Staphylococcus or killing the same.

The present disclosure relates to a novel Lactobacillus plantarum CJLP17 strain having acid resistance, bile resistance, and an immune-enhancing activity, and to a composition comprising the Lactobacillus plantarum CJLP17 strain.

An extract of an herbal composition comprising at least two different dried plants useful as antimicrobial and/or antibiofilm agent in the treatment or prevention of microbial infections caused by bacteria, such as for example Escherichia, Klebsiella, Listeria, Pseudomonas, Salmonella, Streptococcus or Staphylococcus, or by fungi, such as for example is herein described. It has been found that in such extract, the active ingredients exert their biological effects in a synergistic manner. The extract may constitute the active ingredient of a food supplement, a nutraceutical, pharmaceutical or cosmetic composition or a functional food or a food additive. A process for preparing said extract is also described here.

The present invention relates to a bacteriophage-derived recombinant protein having antimicrobial activity against gram-negative bacteria, and the bacteriophage-derived recombinant protein LysSS exhibits killing activity to gram-negative bacteria and thus can prevent or treat infectious diseases caused by bacteria, and can be widely used in antibiotics, disinfectants, food additives, feed additives, and the like, wherein the LysSS uses peptidoglycan, which is a component of the cell wall of bacteria, as a substrate, and exhibits bacterial killing ability due to peptidoglycan degradation and the peptidoglycan exists only in bacteria and not in humans or animals.

The present invention relates to the use of the recombinant antibacterial protein Ablysin for effectively killing multidrug-resistant pathogenic bacteria. The recombinant protein Ablysin of the present invention exhibits apoptosis against antibiotic-resistant Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Enterococcus faecium to prevent or treat infectious diseases caused by these bacteria and thus it can be widely used in antibiotics, disinfectants, food additives, feed additives, and the like. In particular, the Ablysin uses peptidoglycan, which is a component of the cell wall of bacteria, as a substrate, and exhibits bacterial killing ability due to peptidoglycan degradation. The peptidoglycan exists only in bacteria and not in humans or animals, and thus there is an advantage that Ablysin of the present invention is safe because it does not affect humans and animals, and can be applied to the pharmaceutical industry, food industry, biotechnology, etc., as well as can effectively kill bacteria in a target place or a target substance without problems of resistance to antimicrobial agents.